Journal of Clinical Endocrinology & Metabolism, Vol 79, 1082-1085, Copyright © 1994 by Endocrine Society

ARTICLES

Final stature in patients with endogenous Cushing's syndrome

MA Magiakou, G Mastorakos and GP Chrousos
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.

Growth retardation to complete growth arrest is the hallmark of Cushing's syndrome in children and growing adolescents; however, the effect of endogenous hypercortisolism on the final adult stature of these patients is not known. We examined this in 10 children and adolescents with endogenous Cushing's syndrome who were evaluated and successfully treated at the NIH Clinical Center before having completed their growth. The bone age was consistent with the chronological age or accelerated in four of six (67%) and delayed in two of six patients (33%). The pretreatment height of patients with Cushing's syndrome in SD units was -1.7 +/- 1.3 (mean +/- SD), the final adult height -1.3 +/- 0.9, and the midparental height was 0 +/- 0.8. All patients had a compromised final adult stature compared to their midparental height (162.8 +/- 9.0 vs. 171.7 +/- 6.3 cm; P < 0.05). The mean (midparental height - final adult height) +/- SD was 8.9 +/- 7.3 cm. The final adult height in both centimeters and SD units was significantly lower than the midparental height (P < 0.05), whereas it did not differ significantly from the predicted heights by the Bayley-Pinneau and Roche-Wainer-Thissen methods. We conclude that the growth retardation caused during the hypercortisolemic state of Cushing's syndrome is associated with a compromised final adult height, possibly as a result of inadequate postcure catch-up growth.

This article has been cited by other articles:

				L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF]

				D. L. Batista, J. Riar, M. Keil, and C. A. Stratakis Diagnostic Tests for Children Who Are Referred for the Investigation of Cushing Syndrome Pediatrics, September 1, 2007; 120(3): e575 - e586. [Abstract] [Full Text] [PDF]

				L F Chan, H L Storr, P N Plowman, L A Perry, G M Besser, A B Grossman, and M O Savage Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy Eur. J. Endocrinol., April 1, 2007; 156(4): 477 - 482. [Abstract] [Full Text] [PDF]

				D. Chrysis, F. Zaman, A. S. Chagin, M. Takigawa, and L. Savendahl Dexamethasone Induces Apoptosis in Proliferative Chondrocytes through Activation of Caspases and Suppression of the Akt-Phosphatidylinositol 3'-Kinase Signaling Pathway Endocrinology, March 1, 2005; 146(3): 1391 - 1397. [Abstract] [Full Text] [PDF]

				G. Arnaldi, A. Angeli, A. B. Atkinson, X. Bertagna, F. Cavagnini, G. P. Chrousos, G. A. Fava, J. W. Findling, R. C. Gaillard, A. B. Grossman, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5593 - 5602. [Abstract] [Full Text] [PDF]

				H. L. Storr, P. N. Plowman, P. V. Carroll, I. Francois, G. E. Krassas, F. Afshar, G. M. Besser, A. B. Grossman, and M. O. Savage Clinical and Endocrine Responses to Pituitary Radiotherapy in Pediatric Cushing's Disease: An Effective Second-Line Treatment J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 34 - 37. [Abstract] [Full Text] [PDF]

				E. Charmandari, S. M. Pincus, D. R. Matthews, A. Johnston, C. G. D. Brook, and P. C. Hindmarsh Oral Hydrocortisone Administration in Children with Classic 21-Hydroxylase Deficiency Leads to More Synchronous Joint GH and Cortisol Secretion J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2238 - 2244. [Abstract] [Full Text] [PDF]

				E. Charmandari, S. M. Pincus, D. R. Matthews, E. Dennison, C. H. D. Fall, and P. C. Hindmarsh Joint Growth Hormone and Cortisol Spontaneous Secretion Is More Asynchronous in Older Females Than in Their Male Counterparts J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3393 - 3399. [Abstract] [Full Text] [PDF]

				M.-C. Lebrethon, A. B. Grossman, F. Afshar, P. N. Plowman, G. M. Besser, and M. O. Savage Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3262 - 3265. [Abstract] [Full Text]

				R. S. Newfield, G. Kalaitzoglou, T. Licholai, D. Chilton, J. Ashraf, E. B. Thompson, and M. I. New Normocortisolemic Cushing's Syndrome Initially Presenting with Increased Glucocorticoid Receptor Numbers J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 14 - 21. [Abstract] [Full Text]

				B. Boersma and J. M. Wit Catch-up Growth Endocr. Rev., October 1, 1997; 18(5): 646 - 661. [Abstract] [Full Text]

				D. J. Devoe, W. L. Miller, F. A. Conte, S. L. Kaplan, M. M. Grumbach, S. M. Rosenthal, C. B. Wilson, and S. E. Gitelman Long-Term Outcome in Children and Adolescents after Transsphenoidal Surgery for Cushing's Disease J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3196 - 3202. [Abstract] [Full Text] [PDF]

				J. R. Seckl and W. L. Miller How Safe Is Long-term Prenatal Glucocorticoid Treatment? JAMA, April 2, 1997; 277(13): 1077 - 1079. [Abstract] [PDF]